Ameritas Investment Partners, Inc. Mirati Therapeutics, Inc. Transaction History

Ameritas Investment Partners, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 06, 2021	SELL	$144.0 - $179.73 $508,320 - $634,446	-3,530 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$158.92 - $221.61 $13,349 - $18,615	-84 Reduced 2.32%	3,530 $605,000
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $59,310 - $87,938	366 Added 11.27%	3,614 $794,000
Q2 2020 Aug 05, 2020	BUY	$72.01 - $120.39 $47,526 - $79,457	660 Added 25.5%	3,248 $371,000
Q1 2020 May 13, 2020	BUY	$69.78 - $116.21 $15,002 - $24,985	215 Added 9.06%	2,588 $199,000
Q4 2019 Feb 13, 2020	BUY	$70.76 - $128.86 $7,642 - $13,916	108 Added 4.77%	2,373 $306,000
Q3 2019 Nov 14, 2019	BUY	$77.91 - $109.6 $10,284 - $14,467	132 Added 6.19%	2,265 $176,000
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $21,773 - $38,323	366 Added 20.71%	2,133 $220,000
Q1 2019 May 15, 2019	BUY	$43.65 - $78.95 $8,773 - $15,868	201 Added 12.84%	1,767 $130,000
Q3 2018 Nov 13, 2018	BUY	$47.1 - $62.7 $7,065 - $9,405	150 Added 10.59%	1,566 $74,000
Q2 2018 Aug 13, 2018	BUY	$26.05 - $52.4 $36,886 - $74,198	1,416 New	1,416 $70,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.